How is bioequivalence typically assessed in regulatory studies, and what does the 80–125% acceptance window represent?

How is bioequivalence typically assessed in regulatory studies, and what does the 80–125% acceptance window represent?

• A. By comparing geometric mean ratios of Cmax and AUC with a 90% CI; window indicates no clinically meaningful difference.
• B. By comparing arithmetic mean ratios of Cmax and AUC with a 90% CI.
• C. By comparing Cmax values alone with a 90% CI.
• D. By comparing geometric mean ratios of Tmax and AUC with a 90% CI; window indicates no clinically meaningful difference.

Answer: (D)

Bioequivalence is judged by comparing how much and how fast the drug enters the bloodstream from two products. Because pharmacokinetic data are log-normal, we analyze the ratios of geometric means for key exposure metrics, normally Cmax (the peak concentration) and AUC (the total amount absorbed over time). Regulators look at the 90% confidence intervals for these ratios (test vs reference) and require them to fall entirely within 80% to 125%. When both Cmax and AUC meet this criterion, the products are considered bioequivalent, meaning their rate and extent of absorption are not meaningfully different. Tmax, while often recorded, is not used to define bioequivalence in the primary decision because it can be highly variable and does not directly reflect total exposure. The 80–125% window specifically relates to the comparison of exposure (AUC) and rate (Cmax) of the two products, indicating no clinically meaningful difference in how the drug is absorbed.

Bioequivalence is judged by comparing how much and how fast the drug enters the bloodstream from two products. Because pharmacokinetic data are log-normal, we analyze the ratios of geometric means for key exposure metrics, normally Cmax (the peak concentration) and AUC (the total amount absorbed over time). Regulators look at the 90% confidence intervals for these ratios (test vs reference) and require them to fall entirely within 80% to 125%. When both Cmax and AUC meet this criterion, the products are considered bioequivalent, meaning their rate and extent of absorption are not meaningfully different.

Tmax, while often recorded, is not used to define bioequivalence in the primary decision because it can be highly variable and does not directly reflect total exposure. The 80–125% window specifically relates to the comparison of exposure (AUC) and rate (Cmax) of the two products, indicating no clinically meaningful difference in how the drug is absorbed.